Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02091388 · ClinicalTrials.gov registry record · Phase 1
Bioavailability of LY03004 and Risperdal® Consta®
A Phase 1 study, sponsored by Luye Pharma Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 108
- Enrollment target
NCT02091388 is a Phase 1 study that has completed, run by Luye Pharma Group. The registered enrollment target is 108 participants.
The verdict
NCT02091388, a Phase 1 study, has completed, sponsored by Luye Pharma Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 108 participants
- Enrollment target
Study Summary
This study is to assess the bioavailability of LY03004 compared to Risperdal Consta as well as the evaluate the safety and tolerability and preliminary efficacy of LY03004 with repeat injections
Interventions
- DRUG Risperdal® Consta®
- DRUG LY03004
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02091388
The ClinicalTrials.gov registry entry for NCT02091388 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Luye Pharma Group, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Risperdal® Consta® is the first listed.
NCT02091388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02091388 about?
NCT02091388 is a clinical study titled "Bioavailability of LY03004 and Risperdal® Consta®". This study is to assess the bioavailability of LY03004 compared to Risperdal Consta as well as the evaluate the safety and tolerability and preliminary efficacy of LY03004 with repeat injections
What is the current status of trial NCT02091388?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2014-09. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02091388?
The interventions under investigation include: Risperdal® Consta® (DRUG), LY03004 (DRUG).
Who is sponsoring clinical trial NCT02091388?
This trial is sponsored by Luye Pharma Group, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.